Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.

ABSTRACT:

Context

Pediatric acute lymphoblastic leukemia (ALL) is the prototype for a drug-responsive malignancy. Although cure rates exceed 80%, considerable unexplained interindividual variability exists in treatment response.

Objectives

To assess the contribution of inherited genetic variation to therapy response and to identify germline single-nucleotide polymorphisms (SNPs) associated with risk of minimal residual disease (MRD) after remission induction chemotherapy.

Design, setting, and patients

Genome-wide interrogation of 476,796 germline SNPs to identify genotypes that were associated with MRD in 2 independent cohorts of children with newly diagnosed ALL: 318 patients in St Jude Total Therapy protocols XIIIB and XV and 169 patients in Children's Oncology Group trial P9

SUBMITTER: Yang JJ 

PROVIDER: S-EPMC2664534 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature